| 000 | 01292 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250516025423.0 | ||
| 264 | 0 | _c20110719 | |
| 008 | 201107s 0 0 eng d | ||
| 022 | _a1527-3350 | ||
| 024 | 7 |
_a10.1002/hep.24262 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPawlotsky, Jean-Michel | |
| 245 | 0 | 0 |
_aTreatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. _h[electronic resource] |
| 260 |
_bHepatology (Baltimore, Md.) _cMay 2011 |
||
| 300 |
_a1742-51 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntiviral Agents _xpharmacology |
| 650 | 0 | 4 | _aDrug Resistance, Viral |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aHepacivirus _xdrug effects |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xtherapeutic use |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xtherapeutic use |
| 650 | 0 | 4 |
_aProtease Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 |
_aRibavirin _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Failure |
| 773 | 0 |
_tHepatology (Baltimore, Md.) _gvol. 53 _gno. 5 _gp. 1742-51 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/hep.24262 _zAvailable from publisher's website |
| 999 |
_c20647539 _d20647539 |
||